米国のmRNA合成原料市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、セグメント別予測、2025年～2033年

米国のmRNA合成原料市場のサマリー

米国のmRNA合成原料市場規模は、2024年には5億4,100万米ドルと推計され、2033年には9億3,220万米ドルに達すると予測され、2025年から2033年までのCAGRは6.57%で成長すると予測されます。この成長の背景には、mRNA技術に対する学術的・産業的関心の高まり、mRNA研究への資金提供の増加、mRNAベースのワクチンの利点に対する認識の高まりがあります。

さらに、RNA技術の治療用途の増加は、予測期間中にmRNA合成原料に大きな需要をもたらすと予想されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場課題分析
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析

第4章 タイプビジネス分析

• タイプセグメントダッシュボード
• 米国のmRNA合成原料市場変動分析
• 米国のmRNA合成原料市場規模と動向分析（タイプ別、2021～2033年）
• キャッピング剤
  • CleanCap試薬
  • ARCA（アンチリバースキャップアナログ）
  • その他
• ヌクレオチド
  • 修飾核酸
  • 天然核酸
• プラスミドDNA
• 酵素
  • ポリメラーゼ
  • RNase阻害剤
  • DNase
  • その他
• その他

第5章 用途ビジネス分析

• 用途セグメントダッシュボード
• 米国のmRNA合成原料市場の用途変動分析
• 米国のmRNA合成原料市場規模と動向分析（用途別、2021～2033年）
• 治療薬製造
• ワクチン製造
• その他の用途

第6章 最終用途ビジネス分析

• 最終用途セグメントダッシュボード
• 米国のmRNA合成原料市場の最終用途変動分析
• 米国のmRNA合成原料市場規模と動向分析（最終用途別、2021～2033年）
• バイオ医薬品および製薬会社
• CROとCMO
• 学術調査機関

第7章 競合情勢

• 企業分類
• 戦略マッピング
• 企業市況分析、2024年
• 企業プロファイル/上場企業
  • F. Hoffmann-La Roche Ltd.
  • Jena Bioscience GmbH
  • Merck KGaA
  • Yeasen Biotechnology（Shanghai）Co., Ltd
  • BOC Sciences
  • Thermo Fisher Scientific, Inc.
  • Maravai LifeSciences
  • New England Biolabs
  • Creative Biogene
  • HONGENE
  • Evonik Industries AG
  • GENEVANT SCIENCES CORPORATION

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. mRNA synthesis raw materials market, by type, 2021 - 2033 (USD Million)
• Table 4 U.S. mRNA synthesis raw materials market, by application, 2021 - 2033 (USD Million)
• Table 5 U.S. mRNA synthesis raw materials market, by end use, 2021 - 2033 (USD Million)
• Table 6 Key companies undergoing expansions.
• Table 7 Key companies undergoing acquisitions.
• Table 8 Key companies undergoing collaborations.
• Table 9 Key companies launching new products/services.
• Table 10 Key companies undertaking other strategies.

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Market formulation & validation
• Fig. 6 U.S. mRNA synthesis raw materials market: market outlook
• Fig. 7 U.S. mRNA synthesis raw materials competitive insights
• Fig. 8 Parent market outlook
• Fig. 9 U.S. mRNA synthesis raw materials market driver impact
• Fig. 10 U.S. mRNA synthesis raw materials market restraint impact: Type & services movement analysis
• Fig. 11 U.S. mRNA synthesis raw materials market: Type outlook and key takeaways
• Fig. 12 Capping agents market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 13 CleanCap reagents market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 14 ARCA (anti-reverse cap analog) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 15 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 16 Nucleotides market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 17 Modified nucleic acids market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 18 N1-methylpseudouridine-triphosphate market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 19 5-Methylcytidine triphosphate (5mCTP) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 20 Others market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 21 Natural nucleic acids market estimates and forecasts,2021 - 2033 (USD Million)
• Fig. 22 Adenine market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Guanine market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 24 Cytosine market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 25 Uracil market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 26 Plasmid DNA market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Enzymes market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Polymerase market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 RNase inhibitor market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 30 DNase materials market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 32 Others market estimates and forecasts,2021 - 2033 (USD Million)
• Fig. 33 U.S. mRNA synthesis raw materials market: Application movement analysis
• Fig. 34 U.S. mRNA synthesis raw materials market: Application outlook and key takeaways
• Fig. 35 Vaccine production market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 36 Therapeutics production market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 37 Other application market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 38 U.S. mRNA synthesis raw materials market: End Use movement analysis
• Fig. 39 U.S. mRNA synthesis raw materials market: End Use outlook and key takeaways
• Fig. 40 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 41 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 42 CROs CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 43 Market share of key market players - U.S. mRNA synthesis raw materials market

U.S. mRNA Synthesis Raw Materials Market Summary

The U.S. mRNA synthesis raw materials market size was estimated at USD 541.0 million in 2024 and is projected to reach USD 932.2 million by 2033, growing at a CAGR of 6.57% from 2025 to 2033. This growth is attributed to the growing academic & industrial interest in mRNA technology, increasing funding for mRNA research, and rising awareness of the advantages of mRNA-based vaccines.

Moreover, the increasing therapeutic applications of RNA technology are anticipated to provide significant demand for the mRNA synthesis raw materials over the forecast period.

U.S. mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. mRNA synthesis raw materials market report based on type, application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Capping Agents
• CleanCap Reagents
• ARCA (Anti-Reverse Cap Analog)
• Others
• Nucleotides
• Modified Nucleic Acids
  • N1-methylpseudouridine-triphosphate
  • 5-Methylcytidine triphosphate (5mCTP)
  • Others
• Natural Nucleic Acids
  • Adenine
  • Guanine
  • Cytosine
  • Uracil
• Plasmid DNA
• Enzymes
• Polymerase
• RNase Inhibitor
• DNase
• Others
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Vaccine Production
• Therapeutics Production
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Type Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Primary Research
• 1.5. Information or Data Analysis:
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing academic & industrial interest in mRNA technology
    • 3.2.1.2. Advantages of mRNA vaccines
    • 3.2.1.3. Increasing funding for mRNA research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
    • 3.2.2.2. High cost of mRNA synthesis raw materials
  • 3.2.3. Market Challenge Analysis
    • 3.2.3.1. Lack of long-lasting and affordable manufacturing processes
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
• 4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Capping Agents
  • 4.4.1. Capping agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. CleanCap Reagents
    • 4.4.2.1. CleanCap reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. ARCA (Anti-Reverse Cap Analog)
    • 4.4.3.1. ARCA (anti-reverse cap analog) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Nucleotides
  • 4.5.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Modified Nucleic Acids
    • 4.5.2.1. Modified nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.2. N1-methylpseudouridine-triphosphate
      • 4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
      • 4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.4. Others
      • 4.5.2.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Natural Nucleic Acids
    • 4.5.3.1. Natural nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. Adenine
      • 4.5.3.2.1. Adenine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.3. Guanine
      • 4.5.3.3.1. Guanine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.4. Cytosine
      • 4.5.3.4.1. Cytosine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.5. Uracil
      • 4.5.3.5.1. Uracil market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Plasmid DNA
  • 4.6.1. Plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Polymerase
    • 4.7.2.1. Polymerase market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. RNase Inhibitor
    • 4.7.3.1. RNase inhibitor market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.4. DNase
    • 4.7.4.1. DNase market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.5. Others
    • 4.7.5.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
• 5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Therapeutics Production
  • 5.4.1. Therapeutics production market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Vaccine Production
  • 5.5.1. Vaccine production market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Application
  • 5.6.1. Other application market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. U.S. mRNA Synthesis Raw Materials Market End Use Movement Analysis
• 6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Biopharmaceutical & Pharmaceutical Companies
  • 6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. CROs & CMOs
  • 6.5.1. CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Academic & Research Institutes
  • 6.6.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. F. Hoffmann-La Roche Ltd.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Jena Bioscience GmbH
    • 7.4.2.1. Overview
    • 7.4.2.2. Product Benchmarking
    • 7.4.2.3. Strategic Initiatives
  • 7.4.3. Merck KGaA
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
    • 7.4.4.1. Overview
    • 7.4.4.2. Product Benchmarking
    • 7.4.4.3. Strategic Initiatives
  • 7.4.5. BOC Sciences
    • 7.4.5.1. Overview
    • 7.4.5.2. Product Benchmarking
    • 7.4.5.3. Strategic Initiatives
  • 7.4.6. Thermo Fisher Scientific, Inc.
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Maravai LifeSciences
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. New England Biolabs
    • 7.4.8.1. Overview
    • 7.4.8.2. Product Benchmarking
    • 7.4.8.3. Strategic Initiatives
  • 7.4.9. Creative Biogene
    • 7.4.9.1. Overview
    • 7.4.9.2. Product Benchmarking
    • 7.4.9.3. Strategic Initiatives
  • 7.4.10. HONGENE
    • 7.4.10.1. Overview
    • 7.4.10.2. Product Benchmarking
    • 7.4.10.3. Strategic Initiatives
  • 7.4.11. Evonik Industries AG
    • 7.4.11.1. Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. GENEVANT SCIENCES CORPORATION
    • 7.4.12.1. Overview
    • 7.4.12.2. Product Benchmarking
    • 7.4.12.3. Strategic Initiatives